ETO is essentially an immune modulator that can counteract excessive activation of CD8 + T cells and reduce the production of pro-inflammatory signals, such as IL-6, IL-10, and IL-18, which helps alleviate persistent inflammation in HLH patients [146, 147]. The gene discussed is CD8A; the disease is hemophagocytic syndrome.